-transparent.png){kind=logo}
BACKGROUND Many ovarian cancer patients will after treatment of the recurrence with cisplatin based therapy enter phase I or II studies with new drugs. Lately, some new agents have shown activity. METHODS The review is based on phase II studies mainly and focuses on paclitaxel (taxol). RESULTS A Canadian/European study of high (175 mg/m2) versus low dose (135 mg/m2), and short (3 hours) versus long (24 hours) infusion confirms the reported activity of paclitaxel in previously treated patients. The preliminary overall response rate in 286 evaluable patients is 18.5%. A dose effect exists regarding neuropathy and neutropenia, and a longer infusion duration results in a higher frequency of grade 4 neutropenia. In a phase III study comparing cisplatin 75 mg/m2 plus cyclophosphamide (750 mg/m2) or plus paclitaxel 135 mg/m2 over 24 hours, the paclitaxel-based combination gave a superior response rate (54% versus 33%) and statistically significant longer progression-free interval. The semisynthetic docetaxel (taxotere) gives an overall response rate of 32% (95% confidence interval 23%-43%). Skin toxicity and edema are dose-limiting factors. Gemcitabine has also shown activity in platinum-resistant patients with an overall response rate of 23% (95% CI 10%-40%). CONCLUSIONS The role of new drugs in first-line therapy remains to be seen. Further development of experimental work for screening and evaluation of new agents is needed.
H H Hansen, and
E A Eisenhauer, and
M Hansen, and
J P Neijt, and
M J Piccart, and
C Sessa, and
J T Thigpen
April 2015,
Clinical advances in hematology & oncology : H&O,
H H Hansen, and
E A Eisenhauer, and
M Hansen, and
J P Neijt, and
M J Piccart, and
C Sessa, and
J T Thigpen
May 1984,
British journal of obstetrics and gynaecology,
H H Hansen, and
E A Eisenhauer, and
M Hansen, and
J P Neijt, and
M J Piccart, and
C Sessa, and
J T Thigpen
February 2008,
Clinical advances in hematology & oncology : H&O,
H H Hansen, and
E A Eisenhauer, and
M Hansen, and
J P Neijt, and
M J Piccart, and
C Sessa, and
J T Thigpen
December 2011,
Annals of oncology : official journal of the European Society for Medical Oncology,
H H Hansen, and
E A Eisenhauer, and
M Hansen, and
J P Neijt, and
M J Piccart, and
C Sessa, and
J T Thigpen
August 1987,
Onkologie,
H H Hansen, and
E A Eisenhauer, and
M Hansen, and
J P Neijt, and
M J Piccart, and
C Sessa, and
J T Thigpen
September 1996,
Medizinische Monatsschrift fur Pharmazeuten,
H H Hansen, and
E A Eisenhauer, and
M Hansen, and
J P Neijt, and
M J Piccart, and
C Sessa, and
J T Thigpen
April 1999,
Praxis,
H H Hansen, and
E A Eisenhauer, and
M Hansen, and
J P Neijt, and
M J Piccart, and
C Sessa, and
J T Thigpen
May 1972,
Ginekologia polska,
H H Hansen, and
E A Eisenhauer, and
M Hansen, and
J P Neijt, and
M J Piccart, and
C Sessa, and
J T Thigpen
July 1978,
Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
H H Hansen, and
E A Eisenhauer, and
M Hansen, and
J P Neijt, and
M J Piccart, and
C Sessa, and
J T Thigpen
January 2021,
Anti-cancer agents in medicinal chemistry,
